# Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation

> **NCT01809847** · PHASE2 · COMPLETED · sponsor: **Technische Universität Dresden** · enrollment: 20 (actual)

## Conditions studied

- Chronic Lymphatic Leukemia

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT01809847
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-09-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01809847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01809847, "Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01809847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*